Keeping up with the news from major medical meetings has become a requirement for healthcare investors.
News & Analysis: Apellis Pharmaceuticals, Inc.
The company is issuing convertible debt to pad its balance sheet and fund late-stage clinical trials.
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
There are good reasons these stocks missed out on the rally.